159 related articles for article (PubMed ID: 6944051)
1. Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
Holdaway IM
Aust N Z J Surg; 1981 Aug; 51(4):345-7. PubMed ID: 6944051
[TBL] [Abstract][Full Text] [Related]
2. Aminoglutethimide as second line endocrine therapy in advanced breast cancer.
Brufman G; Biran S
Anticancer Res; 1986; 6(5):1065-8. PubMed ID: 3800315
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
4. Aminoglutethimide in patients with metastatic breast cancer.
Nemoto T; Rosner D; Patel JK; Dao TL
Cancer; 1989 May; 63(9):1673-5. PubMed ID: 2467735
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
[TBL] [Abstract][Full Text] [Related]
6. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
Nicholson S; Sainsbury JR; Halcrow P; Chambers P; Farndon JR; Harris AL
Lancet; 1989 Jan; 1(8631):182-5. PubMed ID: 2463445
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen.
Brufman G; Biran S
Eur J Surg Oncol; 1985 Mar; 11(1):27-31. PubMed ID: 2985452
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
Smith IE; Harris AL; Morgan M; Ford HT; Gazet JC; Harmer CL; White H; Parsons CA; Villardo A; Walsh G; McKinna JA
Br Med J (Clin Res Ed); 1981 Nov; 283(6304):1432-4. PubMed ID: 6797571
[TBL] [Abstract][Full Text] [Related]
9. Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
Lundgren S; Gundersen S; Klepp R; Lønning PE; Lund E; Kvinnsland S
Breast Cancer Res Treat; 1989 Nov; 14(2):201-6. PubMed ID: 2690972
[TBL] [Abstract][Full Text] [Related]
10. Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer.
Sutherland CM; Muchmore JH; Carter RD
South Med J; 1985 Aug; 78(8):987-9. PubMed ID: 4023793
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P
Oncology; 1988; 45(5):350-3. PubMed ID: 3045726
[TBL] [Abstract][Full Text] [Related]
12. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Kaye SB; Woods RL; Fox RM; Coates AS; Tattersall MH
Cancer Res; 1982 Aug; 42(8 Suppl):3445s-3447s. PubMed ID: 6177404
[TBL] [Abstract][Full Text] [Related]
13. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
Anderson ED; Forrest AP; Levack PA; Chetty U; Hawkins RA
Br J Cancer; 1989 Aug; 60(2):223-6. PubMed ID: 2527549
[TBL] [Abstract][Full Text] [Related]
14. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
[TBL] [Abstract][Full Text] [Related]
15. Second line hormonal therapy with aminoglutethimide in metastatic breast cancer.
Brufman G; Biran S
Acta Oncol; 1990; 29(6):717-20. PubMed ID: 2223141
[TBL] [Abstract][Full Text] [Related]
16. Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status.
Bezwoda WR; Dansey RD; Hesdorffer CS; Browde S
S Afr Med J; 1987 Jul; 72(2):107-9. PubMed ID: 3616780
[TBL] [Abstract][Full Text] [Related]
17. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
[TBL] [Abstract][Full Text] [Related]
18. Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments.
Zambetti M; Brambilla C; Tancini G; Bonadonna G
Tumori; 1987 Aug; 73(4):369-73. PubMed ID: 3660475
[TBL] [Abstract][Full Text] [Related]
19. Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment.
Murray RM; Pitt P
Breast Cancer Res Treat; 1981; 1(2):91-5. PubMed ID: 7348572
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
